Navigation Links
Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Date:3/20/2012

eveloper of highly selective ion channel drugs for the treatment of atrial fibrillation.  Utilising its world-leading expertise in the discovery of potent and selective drugs, Xention is focusing on the potassium channels Kv1.5 and IKACh which are widely recognised by cardiologists as the preferred targets for the prevention of atrial fibrillation.  Xention's lead drug candidate XEN-D0103, a Kv1.5 antagonist, is at the end of phase 1 clinical development and has demonstrated a very high degree of selectivity over non-atrial ion channels.  The company has also developed antagonists of IKACh which are highly potent and selective, and an IKACh development candidate will be selected shortly.

Xention has signed two major research collaborations with Ono Pharmaceutical Co Ltd and the Grϋnenthal Group, which take advantage of its strong experience in ion channel discovery and which are focused on the development of clinical candidates in other therapeutic areas.

Xention is based in Cambridge, UK and employs over 50 people. For further information, please visit http://www.xention.com.

For further information, please contact:

Tim Brears, CEO, Xention Limited, +44(0)1223-493-900

Amber Bielecka / Claire Dickinson, M:Communications, xention@mcomgroup.com, +44(0)20-7920-2352


'/>"/>
SOURCE Xention
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
2. EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
3. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
5. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
6. Gen-Probe Reports Financial Results for the Fourth Quarter of 2011
7. Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results
8. Cepheid Reports Fourth Quarter and Full Year 2011 Results
9. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
11. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... DUBLIN , June 23, 2015 ... has announced the addition of the "Global ... their offering. Market introduction of cancer ... pharmacological and commercialization potential. Chemotherapeutic drugs have dominated ... new modalities have been introduced in past few ...
(Date:6/26/2015)... ... June 26, 2015 , ... ReliantHeart, Inc. , an ... from the first implant of the HeartAssist5® LVAD (HA5) to the 68th consecutive implant, ... , Thrombus that originates in an LVAD is referred to as de novo thrombus. ...
(Date:6/25/2015)... June 25, 2015 Current asthma medications, ... cells or by dilating the airways, can stop ... Hospital, Brigham and Women,s Hospital and Harvard Medical ... asthma: targeting certain sensory nerve endings in the ... Reporting online in the journal Neuron ...
(Date:6/25/2015)... June 25, 2015  BioMed Realty Trust, Inc. (NYSE: ... ILMN ), a world leader in genomics focused ... the genome, has signed a 20-year lease for a ... in Cambridge, England . The project ... the highly skilled workforce in the dynamic research cluster ...
Breaking Biology Technology:Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3Targeting Nerve Endings To Curb Allergic Asthma 2Targeting Nerve Endings To Curb Allergic Asthma 3Targeting Nerve Endings To Curb Allergic Asthma 4Targeting Nerve Endings To Curb Allergic Asthma 5BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 2BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 3
... 5-Year Survival Data for Responding Patients, BERKELEY ... Board: GNTA) announced that the Company has,submitted an ... for its,New Drug Application (NDA) for Genasense(R) (oblimersen ... refractory chronic,lymphocytic leukemia (CLL). The submission is based ...
... CHICAGO, June 5 "AHIMA,s Board of Directors ... strengthen the effort,to address health IT from a strategic ... executives. In addressing the need to,realize real benefits from ... AHIMA will continue working to support the NAHIT,mission and ...
... June 5 BioTrends Research Group, Inc. is,pleased ... II. The report is based on the results ... in the UK, France, Germany, Italy, and Spain.,The ... hyperphosphatemia,and secondary hyperparathyroidism., In the ESA market, ...
Cached Biology Technology:Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 2Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 3Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 4New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists 2
(Date:6/25/2015)... June 25, 2015  Imagine a tool specifically designed ... healthier, happier life. That,s exactly what USANA,s True ... The cutting-edge, portable health program provides a personalized approached ... help improve your lifestyle and nutrition. ... gala Wednesday night, USANA,s THA was honored with the ...
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... Lee Lovering, Ph.D., School of Biosciences, University of ... Award for his seminal work on the structural ... and modify cell walls in bacteria. Natalie Strynadka, ... Lovering,s work: "his spectacular abilities in structural biology ...
... 2012) Aeras and the Infectious Disease Research Institute ... trial of IDRI,s novel tuberculosis vaccine candidate, ID93 + ... safety, tolerability and immunogenicity of the vaccine candidate in ... by Johnson County Clin-Trials in Lenexa, Kansas, in close ...
... risks posed to people who work with tiny fibres used ... Research into the health risks posed by nanofibres ... has pinpointed the lengths at which these fibres are ... from a range of materials including carbon, are about 1,000 ...
Cached Biology News:The American Society for Microbiology honors Andrew Lovering 2As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing 2
...
Request Info...
... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Biology Products: